
How pharma is targeting advances in Alzheimer’s treatments
Listen to this article on the DDW Podcast: Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy… Read More












